BGPartner advises SynAct Pharma on its acquisition of TXP Pharma
SynAct Pharma, a Swedish listed biotechnology company has acquired all shares of TXP Pharma, a privately owned Swiss biotech company, researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases.
Through this acquisition, SynAct Pharma’s position as a leader within therapies for resolution treatment through melanocortin biology is strengthened. The acquisition gives the Swedish Pharma two platforms that complement each other and create a versatility to develop therapies to address the full range of inflammatory and autoimmune diseases.
BGPartner has assisted SynAct Pharma in the negotiations and advised on all Swiss legal matters regarding this international m&a transaction. The team was led by partner Oliver Gnehm (pictured left) and further consisted of partner Alain P. Röthlisberger (pictured centre) and associate Victoria Marty (pictured right).